News | April 25, 2022
Global AYUSH meet ends with promise of Rs 9000 cr. in investment
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
The commitment is expected to generate over 5.56 lakh jobs and positively impact the lives of more than 76 lakh people, the ministry said
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
Subscribe To Our Newsletter & Stay Updated
